BAYZF

OOTC

BAYER AG-REG

Avg. sentiment

0.45bullish

2 news · 90d

7d trend

——

0 news · vs previous 7d (—)

Breakdown

↑ 2• 0↓ 0

Sentiment velocity

+0.000→/day

Acceleration —

Sentiment scores computed by AI · Not investment advice.

No price data available for this ticker.

Top-discussed tickers and the AI sentiment we read. Not advice.

News · 2

SeekingAlpha5/6/2026, 9:03:43 AM
Bayer to buy Perfuse Therapeutics in $2.45B deal, boosting ophthalmology pipeline
Bayer has agreed to acquire Perfuse Therapeutics in a deal valued at $2.45 billion, expanding its ophthalmology pipeline. The transaction represents a significant strategic move for Bayer into eye disease treatments. No financial terms beyond the headline deal value were disclosed in the article.
Sentiment 0.50Relevance 100%
BusinessWire5/6/2026, 6:30:00 AM
Bayer to Acquire Perfuse Therapeutics to Complement Ophthalmology Pipeline
Bayer has announced a definitive agreement to fully acquire Perfuse Therapeutics, a biopharmaceutical company focused on ischemia-induced ocular diseases. The deal gives Bayer full rights to PER-001, a small molecule endothelin receptor antagonist in Phase II development for Glaucoma and Diabetic Retinopathy. The acquisition is intended to complement Bayer's existing ophthalmology pipeline.
Sentiment 0.40Relevance 100%